A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors.Anthony W. Tolcher, Sergio Santillana, Trupti Lingaraj et al.|Journal of Clinical Oncology|2022Cited by 49